112 related articles for article (PubMed ID: 8302789)
1. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.
Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG
Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789
[TBL] [Abstract][Full Text] [Related]
2. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin.
Friess H; Büchler M; Krüger M; Beger HG
Pancreas; 1992; 7(5):516-21. PubMed ID: 1513800
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma.
Sulkowski U; Büchler M; Pederzoli P; Arnold R; Dinse P; Kay A; Haus U; Beger HG
Eur J Cancer; 1999 Dec; 35(13):1805-8. PubMed ID: 10673995
[TBL] [Abstract][Full Text] [Related]
5. Role of octreotide in the treatment of pancreatic cancer.
Ebert M; Friess H; Beger HG; Büchler MW
Digestion; 1994; 55 Suppl 1():48-51. PubMed ID: 8132137
[TBL] [Abstract][Full Text] [Related]
6. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
Fazeny B; Baur M; Prohaska M; Hudec M; Kremnitzer M; Meryn S; Huber H; Grunt T; Tuchmann A; Dittrich C
J Cancer Res Clin Oncol; 1997; 123(1):45-52. PubMed ID: 8996540
[TBL] [Abstract][Full Text] [Related]
7. The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
Iftikhar SY; Watson SA; Morris DL
Br J Cancer; 1991 Jun; 63(6):971-4. PubMed ID: 2069853
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
10. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
11. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
Louhimo J; Alfthan H; Stenman UH; Haglund C
Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
[TBL] [Abstract][Full Text] [Related]
12. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns of Serum CEA and CA199 for Evaluating the Response to First-line Chemotherapy in Patients with Advanced Gastric Adenocarcinoma.
He B; Zhang HQ; Xiong SP; Lu S; Wan YY; Song RF
Asian Pac J Cancer Prev; 2015; 16(8):3111-6. PubMed ID: 25921105
[TBL] [Abstract][Full Text] [Related]
14. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
15. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
[TBL] [Abstract][Full Text] [Related]
16. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
17. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
18. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
20. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas.
Rosenberg L; Barkun AN; Denis MH; Pollak M
Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
